PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide derived from alpha melanocyte stimulating hormone (melanotan II). It is a nonselective melanocortin receptor agonist that acts most specifically at the MC4R receptor. PT-141 received FDA approval in June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women, making it the first subcutaneous injectable indicated for female sexual desire disorder.

Unlike phosphodiesterase-5 inhibitors, which work peripherally through nitric oxide and vasodilation of the corpus cavernosum, PT-141 works centrally. This distinction shapes how clinicians frame it with patients: it targets desire and arousal circuitry, not the sexual event itself.

Mechanism and central effects

MC4R is expressed in the hypothalamus, the medial preoptic area, the paraventricular nucleus, and the limbic system and reward centers. Agonism in these regions upregulates dopamine and some norepinephrine, the primary pathway implicated in sexual behavior modulation. A 2022 functional MRI study of 31 women showed MC4R agonism enhanced cerebellar and supplementary motor area activity during erotic stimulus and reduced secondary somatosensory self-monitoring. The FDA officially lists the precise mechanism for desire improvement as unknown.

The peptide also engages MC1R on melanocytes, which mediates melanin expression and can produce focal hyperpigmentation. MC3R activity in the hypothalamus may contribute to decreased appetite. Subcutaneous dosing is fully bioavailable, reaches maximum concentration within an hour, and has a half life of roughly two and a half hours, cleared mainly through renal excretion.

Clinical evidence and use

The ReConnect phase three trial enrolled 1,247 participants and showed statistically significant improvement in desire and reduction in distress versus placebo. A key limitation: it did not increase satisfying sexual events versus placebo. A 52-week open-label extension sustained the desire improvement with no new safety signals. Off-label male use for erectile dysfunction and low libido has been explored in phase one and two trials, including combination with PDE5 inhibitors for non-responders, but no phase three male data exists.

Typical female dosing is 1.75 mg subcutaneously about 45 minutes before anticipated activity, with no more than one dose per 24 hours and up to eight doses per month. Receptor desensitization informs this monthly ceiling. Nausea is most common with the first dose, affecting up to 40% of patients, and declines with continued use; an antiemetic may be considered.

Key clinical points

• PT-141 is a nonselective melanocortin agonist acting centrally at MC4R; the FDA indication is premenopausal hypoactive sexual desire disorder.
• It improves desire and reduces distress but does not increase the frequency or satisfaction of sexual events, so counsel on expectations.
• It is contraindicated in uncontrolled hypertension and known cardiovascular disease; transient blood pressure rises resolve within about 12 hours.
• Hyperpigmentation via MC1R is more likely with frequent dosing and in darker skin and warrants discussion and skin monitoring.
• Naltrexone interaction and slowed gastric motility can affect concurrent oral medications; review the medication list before starting.